KRAS and cancer: In recent preclinical reports, BI-1823911 appears to be more powerful than sotorasib and adagrasib.392,393 BI-1823911 has displayed promising effects in preclinical models in combination with the pan-KRAS SOS1 inhibitor BI-1701963.392 Currently, BI-1823911 is undergoing a Phase I trial (NCT04973163) to assess its safety and effectiveness both as a monotherapy and in combination with BI-1701963 (SOS1 inhibitor) in different types of advanced cancers, including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer.